These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32853135)

  • 21. Management of advanced prostate cancer in Hong Kong: Insights from an APCCC-Derived survey.
    Poon DM; Ma WK; Chan TW; Ho FK; Ho LY; Leung AK; Leung SY; Sze HC; Kwong PW; Chan ES
    Asia Pac J Clin Oncol; 2019 Oct; 15 Suppl 6():8-13. PubMed ID: 31642191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
    Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
    Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer.
    Dandapani SV; Wong J; Twardowski P
    Cancer Biother Radiopharm; 2020 Sep; 35(7):490-496. PubMed ID: 32762539
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study.
    Lowentritt B; Pilon D; Waters D; Rossi C; Muser E; Kurteva S; Shah A; Khilfeh I; Du S; Ellis L; Lefebvre P; Brown G
    Urol Oncol; 2023 May; 41(5):252.e19-252.e27. PubMed ID: 37080833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.
    Lowentritt B; Pilon D; Khilfeh I; Rossi C; Muser E; Kinkead F; Waters D; Ellis L; Lefebvre P; Brown G
    Urol Oncol; 2023 May; 41(5):253.e1-253.e9. PubMed ID: 37061452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
    Tohi Y; Kato T; Kobayashi K; Daizumoto K; Fukuhara H; Ohira S; Katayama S; Shimizu R; Takamoto A; Nishimura K; Ikeda K; Nagami T; Hayashida Y; Hirama H; Naito H; Tomida R; Sasaki Y; Yamamoto S; Shimizu S; Sugimoto M;
    Jpn J Clin Oncol; 2024 Feb; 54(2):167-174. PubMed ID: 37840362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.
    Yanev I; Gatete J; Aprikian AG; Guertin JR; Dragomir A
    Curr Oncol; 2022 May; 29(5):3393-3424. PubMed ID: 35621665
    [No Abstract]   [Full Text] [Related]  

  • 29. "Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".
    Jardim DL; Gonçalves E Silva A; Pompeo ASFL; Sarkis AS; Cardoso APG; Sasse AD; Fay AP; Soares A; Pompeo ACL; Carneiro A; Kann AG; Fogassa C; De Freitas CH; Chade DC; Herchenhorn D; De Almeida DVP; Da Rosa DAR; Wiermann EG; Schutz FAB; Kater FR; De Moura F; Korkes F; Meyer F; De Oliveira FNG; Sabino F; Almeida GL; Avanço G; Guimaraes GC; Lemos GC; Carvalhal GF; Kim H; Morbeck IP; Campagnari JC; Rinck JA; Da Ponte JRT; Da Trindade KM; Atem L; Borges L; Nogueira LM; Batista LTEA; Maia MC; Sadi MV; Rocha MAA; Luz MA; Smaletz O; Lages PSM; Matuda RMK; Reis RBD; Indio RF; Fernandes RC; Cavallero SR; Souza VC; Busato W; Alfer W; Maluf F
    Clin Genitourin Cancer; 2023 Apr; 21(2):e58-e69. PubMed ID: 36266221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
    Lorente D; Ravi P; Mehra N; Pezaro C; Omlin A; Gilman A; Miranda M; Rescigno P; Kolinsky M; Porta N; Bianchini D; Tunariu N; Perez R; Mateo J; Payne H; Terstappen L; IJzerman M; Hall E; de Bono J
    Eur Urol Focus; 2018 Mar; 4(2):235-244. PubMed ID: 28753792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
    Maluf FC; Pereira FMT; Serrano Uson PL; Bastos DA; Rodrigues da Rosa DA; Wiermann EG; Schutz FA; Kater FR; de Oliveira FNG; Marques Monteiro FS; de Pádua FV; Orlandi FJ; de Almeida Saito HP; Ayadi M; Boghikian PS; Kopp RM; de Carvalho RS; de Fogace RN; de Araújo Cavallero SR; Aguiar S; Souza VC; Sommer SG
    JCO Glob Oncol; 2021 Apr; 7():550-558. PubMed ID: 33856896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer.
    Zhang J; Sun J; Bakht S; Hassan W
    Curr Mol Pharmacol; 2022; 15(1):159-169. PubMed ID: 34102978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
    Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
    Eur Urol; 2023 Mar; 83(3):267-293. PubMed ID: 36494221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
    Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
    Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.
    Gul A; Garcia JA; Barata PC
    Cancer Manag Res; 2019; 11():7253-7262. PubMed ID: 31534371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
    Cattrini C; Caffo O; De Giorgi U; Mennitto A; Gennari A; Olmos D; Castro E
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
    Dror CM; Chi KN
    Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
    Barata PC; Leith A; Ribbands A; Montgomery R; Last M; Arondekar B; Ivanova J; Niyazov A
    Oncologist; 2023 Sep; 28(9):780-789. PubMed ID: 37014080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017.
    Saad M; Alip A; Lim J; Abdullah MM; Chong FLT; Chua CB; Ismail F; Khong RK; Lim CS; Loh CS; Malek R; Mohd Ghani KA; Md Noor I; Md Yusoff NA; Nasuha NA; Razack A; Soo Hoo HF; Sundram M; Tan HM; Thiagarajan M; Teh GC; Voon PJ; Ong TA
    BJU Int; 2019 Sep; 124(3):373-382. PubMed ID: 31077523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.
    Shayegan B; Wallis CJD; Hamilton RJ; Morgan SC; Cagiannos I; Basappa NS; Ferrario C; Gotto GT; Fernandes R; Roy S; Noonan KL; Niazi T; Hotte SJ; Saad F; Hew H; Park-Wyllie L; Chan KFY; Malone S
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):74-79. PubMed ID: 35197558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.